kuliah ,ebm,apraisal1,2,3 ,4
TRANSCRIPT
-
8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4
1/17
Critical Appraisal
Unit Pengembangan & Evaluasi Pendidikan ( UPEP )
FacultY of MedicinEUniversitY of SriwijayA
Palembang
-
8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4
2/17
UPEP FK UNSRIClinical appraisal
The Utility of Diagnostic
The effect of Therapy
Prognosis of disease
Causative / Harm (etiology of disorders)
-
8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4
3/17
UPEP FK UNSRIHow to appraisal ?
Valid ?
Important ?
Aplicable ?
-
8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4
4/17
UPEP FK UNSRIEvidence-Based Guidelines
Effectiveness of Clinical InterventionLevel Type of evidence
Ia Meta-analysis of randomized trial
Ib At least one randomized trial
IIa Well-designed, controlled study
IIb Well-designed, quasi-experimental studyIII Descriptive and comparative studies.
IV Non random study.
V Case serial, expert panel / committee
-
8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4
5/17
UPEP FK UNSRIRecommendations On Clinical Intervention
Grade Nature of Recommendation
A Ia + Ib / ( > I )
B Ia / Ib
C IIa / IIbD III
E IV / V
-
8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4
6/17
UPEP FK UNSRIAppraisal
Prognosis Is this evidence about prognosis valid ?
1. Was a defined, representative sample of patientsassembled at a common (usual early) point in the
course of their disease ?
2. Was patient follow-up sufficiently long and complete ?
3. Were objective outcome criteria applied in a blind
fashion ?4. If sub groups with different prognosis are identified:
- Was there adjustment for important prognostic factors?
- Was there validation in an independent group of test-set patients?
-
8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4
7/17
UPEP FK UNSRIIs this evidence about therapy
(from an individual randomized trial) valid?1. Was the assignment of patients to treatment randomized?
2. Was the randomization concealed?
3. Were the groups similar at the start of the trial?
4. Was follow-up of patients sufficiently long and complete?5. Were all patients analyzed in the groups to which they were
randomized?
Some finer points:
6. Were patients, clinicians, and study personnel kept blind totreatment?
7. Were groups treated equally, apart from the experimentaltherapy?
Elsevier Ltd 2005. Straus et al.: Evidence-based medicine
-
8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4
8/17
UPEP FK UNSRIValid ?
1. Was a defined, representative sample of patients assembledat a common (usual early) point in the course of theirdisease ?
Ideally : entire population who ever live who developed thedisease
How Close the report approaches to Ideal ?
How the disease was defined ?
How the participants were assembled ? From what point in the disease should patients be followed ?
Inception cohort
Exception if only learn about late stage in the disease
-
8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4
9/17
UPEP FK UNSRIValid ?
2. Was patient follow-up sufficiently long
and complete ?
Ideally : every patient in the inception cohort would be followed until
they fully recover or develop one of the other disease outcomes
Study prognosis 100 patients, 4 die, 16 lost to follow up
A Crude case-fatality rate 4,8 % (4/84 x100%)
-
8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4
10/17
UPEP FK UNSRIValid ?
3. Were objective outcome criteria applied
in a blind fashion ?
Diseases affect patients; some are easy to spot and some are moresubtle.
Extreme outcomes ; death or full recovery. (easy to detect)More difficult between them; rediness to work, intensity of residualpaint.
-
8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4
11/17
UPEP FK UNSRIValid ?
4. If sub groups with different prognosis are
identified:
- Was there adjustment for importantprognostic factors?
- Was there validation in an
independent group of test-setpatients?
-
8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4
12/17
UPEP FK UNSRI Is This valid evidence about prognosis
important?
How likely are the outcomes over time ?
-
8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4
13/17
UPEP FK UNSRI
Important ?
How pricise are the prognostic estimates ?The text, tables, graphis of a proper
prognostic study include the confidence
intervals for estimates of prognosis
-
8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4
14/17
UPEP FK UNSRI
Can we applythis valid, important evidenceabout prognosis to our patient?
Are the study patients similar to our own ?
Are the study patients so different from ours that we should not
use the result at all in making prediction for our patients?
-
8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4
15/17
UPEP FK UNSRI
Apply ?
Will this evidence make a clinically important
impact on our conclusions about what to offer or
tell our patient ?
-
8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4
16/17
UPEP FK UNSRI
-
8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4
17/17
UPEP FK UNSRI